Joint-Pain Supplement Tied to Faster Alzheimer's Progression

Live updates

1. 12d ago

   Glucosamine Linked to Faster Alzheimer's Progression and Higher Mortality

   Research indicates the joint supplement glucosamine may accelerate the shift from mild cognitive impairment to Alzheimer's disease. Users face a 25% higher risk of this progression. Evidence also connects the supplement to an increased risk of death.

   What's confirmed:

   • Glucosamine is linked to a 25% higher risk of progressing from mild cognitive impairment to Alzheimer's disease.
   • The supplement is associated with an increased risk of mortality.
   • Glucosamine is a common over-the-counter supplement used for joint pain.

   Still unconfirmed:

   • Glucosamine might increase the general risk for Alzheimer's disease.
   confidence 95%
2. 16d ago

   Glucosamine Supplement Linked to Faster Alzheimer's Decline and Death

   Research from the University of Florida's McKnight Brain Institute indicates that glucosamine can accelerate the transition from mild cognitive impairment to Alzheimer's disease. Users of the supplement face a 25% higher likelihood of progressing to dementia. New data also connects the supplement to an increased risk of death.

   What's confirmed:

   • Glucosamine use is associated with a 25% increase in progression from mild cognitive impairment to dementia.
   • The University of Florida's McKnight Brain Institute conducted the analysis.
   • Findings were published in Nature Metabolism on June 9, 2026.
   • Patients with Alzheimer's who took the supplement were 25% more likely to die within five years compared to non-users.

   Still unconfirmed:

   • Glucosamine may be a potential driver of Alzheimer's disease.
   • The supplement severely worsens dementia and Alzheimer's disease.
   confidence 95%
3. 19d ago

   Glucosamine Supplement Linked to Faster Alzheimer's Progression

   A study from the University of Florida's McKnight Brain Institute suggests glucosamine may accelerate the transition from mild cognitive impairment to Alzheimer's disease. Researchers found a 25% higher likelihood of developing dementia among users of the joint pain supplement. The findings were published in Nature Metabolism on June 9, 2026.

   What's confirmed:

   • Glucosamine is a popular over-the-counter supplement used for joint pain and arthritis.
   • A study published in Nature Metabolism on June 9, 2026, links glucosamine use to a 25% higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease.
   • The research was conducted by the University of Florida's McKnight Brain Institute using a large retrospective analysis of patients.
   • Hyperglycosylation is identified as a metabolic driver of Alzheimer's disease.

   Still unconfirmed:

   • Long-term use of glucosamine may be associated with a link published in the journal Alzheimer's & Dementia.
   confidence 95%